AUTHOR=Nguyen-Khac Florence 

TITLE=“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.826245

DOI=10.3389/fonc.2021.826245

ISSN=2234-943X

ABSTRACT=<p>Although the 17p deletion [del(17p)] is rare in cases of treatment-naive chronic lymphocytic leukemia (CLL), its frequency is higher in refractory/relapsed CLL – particularly in patients undergoing chemo(immuno)therapy. <italic>TP53</italic> disruption (deletion and/or mutation) is the strongest prognostic factor for refractoriness to chemotherapy; the use of Bruton tyrosine kinase inhibitors and BCL2 inhibitors is then indicated. Rare cases of CLL can also harbor translocation or gain of the <italic>MYC</italic> oncogene. “Double-hit CLL” (with del(17p) and <italic>MYC</italic> gain) is associated with a very poor prognosis. The prognostic impact of <italic>TP53</italic> disruption with <italic>MYC</italic> aberrations in patients receiving targeted therapies must now be evaluated.</p>